FDA Changes Its Policy On Exclusivity For Fixed-Combination Products
This article was originally published in The Pink Sheet Daily
Executive Summary
In response to citizen petitions from Gilead, Ferring and Bayer, FDA issued a draft guidance saying future fixed-combination products that include a previously approved active moiety will be eligible for five years of new chemical entity marketing exclusivity.